Financial Daily from THE HINDU group of publications
Wednesday, May 28, 2003

News
Features
Stocks
Port Info
Archives

Group Sites

Corporate - Announcements


Lyka Labs close to sign $10-m deal with European co

Our Bureau

NEW DELHI, May 27

THE Rs 250-crore Lyka Labs Ltd is close to inking a $10-million contract-manufacturing deal with a European company for a drug in the cardio-vascular segment.

The contract estimated at around Rs 50 crore ($10 million) would be spread over 18 months, Mr Amit Bhasin, CEO of Lyka Labs, told Business Line.

As part of the outsourcing contract, Lyka Labs would provide the European MNC with the active pharmaceutical ingredient and intermediates, he said.

With a presence in the anti-infective, cardio-vascular and diabetic segments — Lyka Labs exports to more than 25 countries and has registered about 475 products in different markets. According to company officials, this is expected to touch 750 products in due course. The company has two of its manufacturing units at Tarapur and Ankleshwar.

Lyka Labs expects to close fiscal 2003-04 with a turnover of Rs 200 crore and a net profit of Rs 11 crore, according to company officials.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Fire mishap at GMR sugar plant


Hyundai cries foul against two private insurers
Reva in talks with IFC to raise funds
Lyka Labs close to sign $10-m deal with European co
CESC Mulajore unit to be shut down by Dec
Banking cos exempt from curbs on loans to directors
`Cos Bill is built on theme of confidence'
BILT to buy 38% stake in APR Packaging
`NTC land sale likely to elicit good response'
Super Spinning plans to increase yarn outsourcing
Wipro Tech bullish on infrastructure services
Bajaj Electricals sees Rs 450-cr revenue
Tata Engineering: Powering ahead


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |

Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line